Elkhorn S&P Midcap Materials Portfolio (delisted) (XM)

“Just like any of the groups that follow their leader.” Perfect! Something you know well about.

WTF!!!!!?????

It's available again.

I guess the Lease Agreement fell through for whoever tried.

Someone snatched it up.

https://www.loopnet.com/Listing/140-LeGrand-Ave-Northvale-NJ/34581968/

This listing is not currently bei

Ok . . .

Gary, the good news is that multiple units can be installed in parallel. Attached another paragraph from AI.

You don’t need a lead unit unless you want one — regulators allow all EDEN units to be installed, IQ’d, OQ’d, and PQ’d in parallel, or you can qualify one lead unit first and

Why? They keep reporting with cost without splitting against a maxed structure. Where is the money coming from , revenue? Of course not, this is a scam. 🤔

CONSERVATORSHIP = "Conserve and Preserve" is the Law (not Reverse Dump on the Shareholders like some penny fraud stock).

How’s come no one wants to borrow my shares to short? 

No "pump" going on,
just retail putting together some pieces of a puzzle,..
hence my avatar.

Cheers

https://x.com/Tickerwire/status/2063581211507966038?s=20

$FMCC~ $FNMA~

If they don’t dilute, this is a market cap play.

If they don’t dilute, this is a market cap play.

It's an exceedingly complex (and high stakes) endeavor.

The nuances of which virtually no one can grasp and it's going to take over a decade to resolve.

Starting when ? Starting from Bitcoins' (and cryptos) inception.

https://investorshub.advfn.com/uimage

New IBM Study Finds CIOs and CTOs Face Growing AI Control Gap as Enterprise Deployment ScalesJune 8, 2026 12:01 AM
PR Newswire (US) Most surveyed technology leaders are accountable for systems they don't fully controlOnly 11% o

🎁 A gift from Plato! 😎https://investorshub.advfn.com/uimage/uploads/2026/6/8/trfmgcagr_circles_-_Copy.png

BIEL PPS-Acceleration Actions To Help Electrome
The Billion-Dollar Pattern Playing Out Right Now: BIEL / Electrome (BIEL)
If you’ve been in the retail trading space for the last decade, you’ve watched the exact same script play out across GME, AMC, Tesla, Palantir, and NIO.

You may buy or sell a position at any time? Wow! That makes you exactly the same as every single person that has ever invested on the stock market. Thanks for the heads up, all of us will eagerly be awaiting and watching to see if you buy or sell a position. We are on edge! Will it be a BUY or a SEL

At this point I've resigned myself to the thought that my investment is gone. Was only 5k cdn so not totally a huge loss but enough. Lesson here is that anything OTC is a gamble. I bet red. I lost. See you around.

BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the RegionJune 8, 2026 12:00 AM
Business Wire BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today

Methinks, to be honest with you, one of the things that makes me nervous about SKS is he is carrying extra weight and I want him to live a long time!!! With these miracle weight loss drugs, I wonder if he has tried one?! Concerned in Connecticut. Anyway, they should just get rid of this mess with

Hopefully mid .20’s this week.
That would exceed any expectations I have, but I will not complain. 

Just found this article which helps explain the value of Ultranet for IQSTEL, that is, other than the obvious boost in margins and large contribution towards achieving positive net income for the entire company. Keep scrolling down as it has breaks in the text.

https://af

True on Vyvanse, BUT Vyvanse has some structural advantages for us:

-Vyvanse is a controlled substance (DEA sets a ceiling on the supply, each company has to battle for their allotment of quota and the better managing companies take market share)

-It and the Adderalls h

You are right about one thing only: I will be paid the day of the buyout just by holding my 3 million shares.

You talk bs because you don’t understand big numbers and the dynamics of real world genetics revenues attrition